Number and Percentage of Patients With Adverse Events in the Placebo-controlled Study1

 
NAGLAZYME (galsulfase) (n=19)
Placebo (n=20*)
Adverse Event
Patients, n(%)
Patients, n(%)
All
19 (100)
20 (100)
Abdominal Pain
9 (47)
7 (35)
Ear Pain
8 (42)
4 (20)
Arthralgia
8 (42)
5 (25)
Pain
6 (32)
1 (5)
Conjunctivitis
4 (21)
0
Dyspnea
4 (21)
2 (10)
Rash
4 (21)
2 (10)
Chills
4 (21)
0
Chest Pain
3 (16)
1 (5)
Pharyngitis
2 (11)
0
Areflexia
2 (11)
0
Corneal Opacity
2 (11)
0
Gastroenteritis
2 (11)
0
Hypertension
2 (11)
0
Malaise
2 (11)
0
Nasal Congestion
2 (11)
0
Umbilical Hernia
2 (11)
0
Hearing Impairment
2 (11)
0
*One of the 20 patients in the placebo group dropped out after week 4 infusion.

CLINIC FINDER

Find an MPS VI clinic near you

Miles

NAGLAZYME.com does not warrant or guarantee the accuracy of information provided in the Clinic Locator.

Share This

Know someone else who could benefit from NAGLAZYME.com? Forward to a family member, MPS VI patient, friend, or colleague. Simply fill out the fields below and click Send.

Who is your message being sent to?

All fields are required.

Message [to HCPs]

(Recipient’s Name), I recently visited NAGLAZYME.com and found it to be immensely informative regarding MPS VI pathophysiology, diagnosis, and treatment. I thought you might find it beneficial for your practice and your patients.
Go to NAGLAZYME.com now

(Recipient’s Name), I recently visited NAGLAZYME.com and found some great information about MPS VI, available treatments, support services, and more. I thought you’d also be interested!
Go to Naglazyme.com now

Sincerely,
(Sender Name)

Clicking the Send button signifies that you have read and agree to our Privacy Notice and Terms of Use. Users may read our full Privacy Notice and Terms of Use by clicking the links provided

X

Please check the Form for errors and resubmit.

Sign up for Email Updates

Be sure to receive updates on MPS VI and NAGLAZYME® (galsulfase). Simply fill out the required fields, then press Sign Up.


All fields are required.

I would like to receive Newsletters by mail.

By checking this box and clicking SUBMIT below, I confirm I am at least 18 years old; confirm I agree to BioMarin’s Privacy Policy and CCPA Notice and Terms of Use; consent to BioMarin, its successors, agents, and/or assigns using the email address I have provided to keep me informed about news and developments, market research or surveys, or other opportunities that may be of interest to me; and confirm I understand these communications/materials may contain information that markets or advertises BioMarin products, goods, or services.*

Please Verify Captcha!

Clicking the Sign Up button signifies that you have read and agree to our Privacy Notice and Terms of Use. Users may read our full Privacy Notice and Terms of Use by clicking the links provided..

  • Prescribing Information
  • Important Safety Information
  • Sign up
  • Clinic Finder
  • Share
  • Go to HCP site >
Naglazyme
 
    • About MPS VI
      • What Happens in MPS VI?
      • What Does MPS VI Do to the Body?
      • Rapidly and Slowly Progressing MPS VI
      • How Is MPS VI Diagnosed?
    • About NAGLAZYME
      • How Does NAGLAZYME Work?
      • Benefits of NAGLAZYME
      • Safety Information
    • Taking NAGLAZYME
      • Getting Started
      • Finding an Infusion Center
      • Home Infusion
      • Treatment Tips
      • Keeping Your Treatment on Track
    • Financial & Care Support
      • Contact BioMarin RareConnections™
University of Oklahoma Health Sciences Center
Posted on January 28, 2015 in: |Jump To Comments

Comments are closed.

CONTACT US

BioMarin Pharmaceutical Inc., Novato, CA 94949

BioMarin RareConnections™ 1-866-906-6100

Proud supporter of the MPS VI CommunityBIOMARIN
  • Terms of Use
  • Contact Us
  • Privacy Notice
  • Site Map
  • Cookie Preferences
© 2023 BioMarin Pharmaceutical Inc. All Rights Reserved. USNGZ0057 1020